Experimental immune cell therapy for advanced cancers shows early promise but trial halted

NCT ID NCT05729399

Terminated Disease control Sponsor: Grit Biotechnology Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tested a personalized therapy called GT201, made from a patient's own tumor-fighting immune cells (TILs), for advanced solid tumors. Only 6 people were enrolled before the study was terminated. The treatment involved intensive chemotherapy followed by infusion of the immune cells and a supportive drug. The main goal was to check safety, but the small size and early stop mean we cannot draw firm conclusions about effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: autologous tumor-infiltrating lymphocyte injection (GT201)
What this could lead to: If successful, this approach could point toward a new treatment option for advanced solid tumors using a patient's own immune cells.
What could go wrong: This was a very early, small trial that was terminated early with only 6 participants. The therapy involves intensive chemotherapy and carries risks like severe immune reactions and infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR

Contacts and locations

Locations

The Affiliated Hospital of Xuzhou Medical University

Xuzhou, Jiangsu, China
The First Affiliated Hospital of Soochow University

Suzhou, Jiangsu, 215006, China
The First Affiliated Hospital of Zhengzhou University

Zhengzhou, Henan, 450000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.